Impact of Rutin and Vitamin C Combination on Oxidative Stress, Insulin Sensitivity and Lipid Profile in Type 2 Diabetic Patients
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03437902 |
Recruitment Status :
Completed
First Posted : February 19, 2018
Last Update Posted : May 16, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Type 2 Diabetes Mellitus | Dietary Supplement: Rutin in combination with Vitamin C Dietary Supplement: Vitamin C | Phase 2 Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 53 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Evaluation of the Impact of Rutin and Vitamin C Combination on Oxidative Stress, Insulin Sensitivity and Lipid Profile in Type 2 Diabetic Patients |
Actual Study Start Date : | February 24, 2018 |
Actual Primary Completion Date : | May 15, 2018 |
Actual Study Completion Date : | May 15, 2018 |

Arm | Intervention/treatment |
---|---|
Experimental: Rutin C group
patients will receive Rutin 60 mg in combination with vitamin C 160 mg three times daily in addition to usual antidiabetic treatment for 8 weeks..
|
Dietary Supplement: Rutin in combination with Vitamin C
Rutin and Vitamin C will be supplied as tablets containing 60 mg Rutin and 160 mg Vitamin C. The use of Rutin and Vitamin C will be under the trade name of RUTA C 60 ® manufactured by KAHIRA PHARM.& CHEM. IND. Company |
Experimental: Vitamin C group
patients will receive vitamin C 500 mg once daily in addition to usual antidiabetic treatment for 8 weeks.
|
Dietary Supplement: Vitamin C
Vitamin C will be supplied as capsules containing500 mg of Vitamin C. The use of Vitamin C will be under the trade name of C-Retard ® manufactured by HIKMA Quality Company.
Other Name: Ascorbic acid |
No Intervention: Control group
patients will receive their usual antidiabetic treatment only for 8 weeks.
|
- Oxidative stress marker (MDA) and antioxidant capacity (SOD) in diabetic patients [ Time Frame: Two months ]Effect of Rutin and vitamin C combination or vitamin C alone on oxidative stress marker (MDA) and on antioxidant capacity (SOD) in diabetic patients after 8 weeks of treatment.
- Insulin resistance in diabetic patients . [ Time Frame: Two months ]Effect of Rutin and vitamin C combination or vitamin C alone on insulin resistance in diabetic patients before i and after treatment for 8 weeks .
- Lipid profile in diabetic patients (TC,TG,HDL-c,LDL-c). [ Time Frame: Two months ]Impact of Rutin and vitamin C combination or vitamin C alone on lipid profile in diabetic patients (TC,TG,HDL-c,LDL-c).
- Quality of life of diabetic patients and this will be evaluated by using Quality of Life Questionnaire (Short Form 36 questions (SF-36)) . [ Time Frame: Two months ]The effect of Rutin and vitamin C combination on quality of life of diabetic patients before and after treatment for 8 weeks and this will be evaluated by using Quality of Life Questionnaire (Short Form 36 questions (SF-36)) .

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 35 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
-
• Patients' age 35 years or older having type 2 diabetes mellitus.
- Patients taking oral diabetic medications (Sulfonylurea) not taking Insulin.
- Able to understand and willing to sign a written informed consent document
Exclusion Criteria:
-
• Pregnant and breast feeding females
• use of vitamin supplements containing vitamin C or other antioxidants.
- patients with renal or hepatic failure.
- patients taking insulin as antidiabetic treatment

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03437902
Egypt | |
Ain Shams University | |
Cairo, Egypt |
Principal Investigator: | sara R Ragheb, master | Ain Shams University |
Responsible Party: | sara ramzy ragheb, Assistant Lecturer, Ain Shams University |
ClinicalTrials.gov Identifier: | NCT03437902 |
Other Study ID Numbers: |
PHCL39 |
First Posted: | February 19, 2018 Key Record Dates |
Last Update Posted: | May 16, 2018 |
Last Verified: | February 2018 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Product Manufactured in and Exported from the U.S.: | No |
Type 2 diabetes Rutin Vitamin C |
oxidative stress Insulin resistance lipid profile |
Diabetes Mellitus, Type 2 Insulin Resistance Diabetes Mellitus Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases Hyperinsulinism |
Vitamins Ascorbic Acid Micronutrients Physiological Effects of Drugs Antioxidants Molecular Mechanisms of Pharmacological Action Protective Agents |